SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- EQUA Specialty Risk Leaders in Cannabis Insurance Solutions
- Understanding Recent Options Trends for Vertiv Hldgs (VRT)
- Understanding JD.com's Options Activity: A Market Insight
- Understanding Recent Options Trends for Meta Platforms Stock
- Opportunity for Investors in WM Technology Securities Case
- Crown Electrokinetics Corp. Faces Decline Yet Sees Revenue Growth
- CMBT Stock: Insights on the 52-Week Low and Future Prospects
- Hub Group Reaches New Heights: A Look at Recent Developments
- US Chamber of Commerce Anticipates New Export Regulations
- Emergent BioSolutions Faces Fallout from Vaccine Production Issues
- Investors Update: Class Action Against Bumble Inc. Soon
- Anticipating Agilent Technologies' Upcoming Earnings Results
- Metagenomi, Inc. Investors Face Key Deadline for Lawsuit
- Important Update for Investors in Humacyte, Inc. (HUMA)
- First Guaranty Bancshares Reaches New Stock Milestone
- Fund Manager Scott Bessent Bets Big on Trump's Economic Policies
- Evaluating the Future of the Magnificent Seven Stocks
- Class Action Lawsuit Against Wolfspeed: What Investors Should Know
- Positive Changes in Overdose Death Rates and What They Mean
- BMO and All Nations Trust Team Up for Indigenous Capital Access
- Ongoing Investigations on Fluence Energy Capture Investor Interest
- Investigation Launched into Zeta Global’s Transparency Issues
- Nippon Sangyo Suishin Kiko Sells Stake in Japan Energy Components
- Lucrotec Achieves Impressive Growth on Deloitte Fast 500 List
- Exploring Strategies for TILT Holdings to Overcome Vape Market Challenges
- TenX Keane Acquisition Corp. Faces Market Headwinds With CTOR Stock
- Silo Pharma Faces Market Turmoil: A Look at Recent Developments
- Negotiations Between EU and China on EV Tariffs Intensify
- Fed Rate Predictions Shift: Higher Neutral Rate Anticipated
- Hearthside Food Solutions Seeks Bankruptcy Protection Amid Debt Issues
- Market Sentiment Shifts: Moderna and Pfizer Show Gains
- Gensler's Departure Sparks Bitcoin Predictions and SHIB Analysis
- Parke Bancorp Reaches New Heights with Stock Surge to $23.5
- LCNB Corp Achieves New Heights with 52-Week High Stock Price
- Navigating Market Turbulence: Intergroup's Stock Insights
- Live Nation Reaches New Heights with Record Stock Performance
- Richmond Mutual Bancorporation Inc. Achieves Record Stock Growth
- NV5 Holdings Faces Challenges as Stock Hits 52-Week Low
- Effective Strategies for Navigating Challenging Psychedelic Experiences
- Ninepoint Partners Reveals November Cash Distribution Plans
- Ninepoint Partners Unveils Cash Distributions for 2024
- Foot Locker Poised for Earnings Growth with Nike Alliance
- Elevating HVAC Services Online: Blue Skies Comfort Air's New Website
- Bitcoin Approaches Milestone with Dogecoin Rising and Ethereum Lagging
- Understanding the Transition from Stability to Economic Volatility
- Exploring Current Trends in Occidental Petroleum Options Trading
- Exploring the Surge in Wells Fargo's Options Trading Activities
- Intel's Options Activity Shows Bullish Investor Sentiment
- Gap, Inc's Strong Earnings and Future Growth Prospects
- Investors Urged to Act Before Deadline in Xerox Lawsuit